- Home
- Companies
- usa oregon
- tumor targeting
Show results for
Refine by
Tumor Targeting Suppliers Serving Usa Oregon
30 companies found
based inPrinceton, NEW JERSEY (USA)
The drug discovery and development process is long and expensive with more failures than successes. At Certara, we anticipate and address your critical drug discovery and development risks and decisions using biosimulation, technology and services. ...
Biological medicines (“biologics” or “large molecule drugs”) now account for 30% of new drug approvals and up to 50% of the pharmaceutical industry’s pipeline. Biologics differ from small molecules because they are much ...
based inBellaire, TEXAS (USA)
C4 Imaging develops innovative medical devices that enable clinicians to personalize patient care through accurate image-guided procedures. The company’s core proprietary technology, C4, is a unique magnetic resonance imaging (MRI) agent that has ...
High dose rate (HDR) brachytherapy, utilizing iridium-192 radioactive sources, is a form of radiotherapy and a standard option for the curative treatment of many forms of cancer. 10 HDR brachytherapy involves temporarily placing an applicator into ...
based inBerkeley, CALIFORNIA (USA)
SonALAsense’s ALA sonodynamic therapy (SDT) is well differentiated from the use of other forms of therapy which have been used for GBM or rGBM. Our use of a MRI-guided focused ultrasound device with ALA is a true drug-device combination, where both ...
We are committed to providing hope in the face of despair with a unique proprietary non-invasive drug-device combination therapy, ALA Sonodynamic Therapy (SDT), for the treatment of recurrent glioblastoma multiforme (rGBM). ...
based inGaithersburg, MARYLAND (USA)
NexImmune is a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIMâ„¢) technology. AIM nanoparticles act as synthetic dendritic cells to deliver ...
based inCambridge, MASSACHUSETTS (USA)
Mersana is a biopharmaceutical company specializing in the discovery and development of antibody-drug conjugate (ADC) therapies to treat patients fighting cancer. Leveraging decades of industry learnings, we have developed proprietary and highly ...
Immunosynthen is our novel immunostimulatory ADC platform designed to take ADCs beyond traditional cytotoxic drugs to targeted stimulation of the innate immune system. Through the safe and efficient delivery of a novel ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
RLX (PD 139530) is a PI3K/Akt/FoxO3a signaling inhibitor, possessing significant therapeutic potential in experimental colon cancer. RLX can effectively modulate the tumor microenvironment, enhancing the efficacy of cancer immunotherapy. RLX ...
based inNeedham, MASSACHUSETTS (USA)
Invicro is an integral part of the REALM IDx, Inc. group, which aims to accelerate personalized medicine, discover novel therapeutic targets and develop innovative therapeutic technologies for unmet medical needs. As a global research partner to the ...
Radiopharmaceutical therapies represent an effective way to treat solid cancers by using tumor targeting small molecules, peptides or biologics to deliver a cytotoxic payload that induces DNA damage in ...
based inSaint-Herblain Cedex, FRANCE
Atlanthera is a drug discovery company focused on bone diseases and bone cancer treatments. The growing medical need and the lack of effective treatments for bone tumors gave rise to Atlanthera in 2011, a drug discovery company focused on bone ...
Specific targeting of tumor bone tissue, Potent antitumor activity, Low systemic toxicity, Prevention of bone ...
based inNanjing, CHINA
ChiRial Biomaterial Co., Ltd. (ChiRial), is a manufacturer of chiral materials through biosynthesis. With 10 years' experience in the field of synthetic biology, the founders of ChiRial have accumulated extensive experience in research, product ...
CRA0066 (R)-5-Methylpyrrolidin-2-one CAS: 21395-93-7. ...
based inUtrecht, NETHERLANDS
At LAVA, we are focused on applying our expertise in gamma-delta T cell engagers. We are building a pipeline of gamma-delta bsTCEs that have applications in both solid and hematologic malignancies. Our lead program, LAVA-051, targets the tumor ...
based inSeoul, SOUTH KOREA
Eutilex is Developing anti-tumor T cell therapy and antibody therapeutics based on its own proprietary immunotherapy technology We set a goal to be a leading company in anti-tumor immunotherapy markets through the technical innovation & early ...
4-1BB mAb-based, tumor antigen targeting bispecific ...
based inFlorham Park, NEW JERSEY (USA)
Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and ...
We are developing CYNK-101 as a combination treatment for multiple cancer indications. CYNK-101 is manufactured from a specific type of immune cell, NK cells, that we extract from postpartum placentas and then genetically engineer to increase cell ...
based in, MASSACHUSETTS (USA)
MtoZ Biolabs is an integrate contract research organization (CRO) providing advanced proteomics, metabolomics, bioinformatics, and biopharmaceutical analysis services to researchers in biochemistry, biotechnology, and biopharmaceutical fields. The ...
based inGarching / Munich, GERMANY
ITM Isotope Technologies Munich SE is a privately owned biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes ...
Targeted Radionuclide Therapy (TRT) or Peptide Receptor Radionuclide Therapy (PRRT) is a medical specialty using very small amounts of radioactive compounds, called radiopharmaceuticals, to diagnose and treat various diseases, like ...
based inBasel, SWITZERLAND
Nuclidium AG specializes in leveraging the unique properties of copper radionuclides in conjunction with tumor-specific molecules to enhance the precision, performance, and accessibility of targeted radiotherapy and diagnostics. Their proprietary ...
Nuclidium AG leverages the unique properties of copper radionuclides to advance precision radiotherapy and diagnostics. Their proprietary CuTrace™ platform combines copper nuclides with tumor-specific molecules, creating ...
based inSouth San Francisco, CALIFORNIA (USA)
We are dedicated to realizing the potential of natural killer (NK) cells for the treatment of cancer. Our proprietary technology is designed to harness the power of these important pathogen-fighting immune cells and is uniquely capable of enhancing ...
Cell therapy, a new approach that uses immune cells to attack tumors, has emerged as one of the most promising breakthroughs in cancer treatment. First generation approaches have focused on T-cells, which have shown great promise in hematologic ...
based inMenlo Park, CALIFORNIA (USA)
Adicet is a biotechnology company engaged in the development of first-in-class off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet has developed a proprietary cell platform process to activate, engineer and ...
based inSan Diego, CALIFORNIA (USA)
Fate Therapeutics (Nasdaq: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. We believe that better cell therapies start with better cells. To ...
T cells engineered with chimeric antigen receptors (CARs) have shown exceptional promise as a potentially curative therapy for patients with certain hematologic malignancies. While most researchers and clinical investigators continue to focus on the ...
based inTuebingen, GERMANY
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation ...
Immatics is developing Adoptive Cell Therapies, which are designed to leverage the power of T cells to actively infiltrate tumor tissue and kill tumor cells in a specific and serial ...
based inGoettingen, GERMANY
We provide the essential products, technologies and expertise to produce biopharmaceuticals reliably and efficiently. In fact, Sartorius has been pioneering and setting the standards for single-use products that are currently used throughout all ...